| Verifiedfields: | changed |
| Watchedfields: | changed |
| Verifiedrevid: | 445236160 |
| Iupac Name: | (1S,2R,5R,7R,8R,9S,11R,13R,14R)-8-[(2''S'',3''R'',4''S'',6''R'')- 4-Dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13- hexamethyl-9-[(''E'')-3-quinolin-3-ylprop-2-enoxy] -3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone |
| Legal Us Comment: | Phase III Clinical Trials |
| Routes Of Administration: | Oral |
| Bioavailability: | Between 35.8 and 60% in animal studies. |
| Metabolism: | Liver |
| Elimination Half-Life: | 1.6, 3.0, 4.5, 5.9 and 6 hours. Mouse, Monkey, Rat, Dog and Human respectively. |
| Excretion: | 7.0% urine 87.2% faeces |
| Cas Number: | 205110-48-1 |
| Atc Prefix: | none |
| Pubchem: | 5282045 |
| Chebi: | 29506 |
| Chembl: | 365528 |
| Unii: | J0086219X6 |
| Kegg: | D02391 |
| Chemspiderid: | 23258189 |
| Smiles: | CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC/C=C/c4cc5ccccc5nc4)C)C)NC(=O)O2)C |
| Stdinchi: | 1S/C42H59N3O10/c1-11-32-42(8)36(44-40(50)55-42)25(4)33(46)23(2)21-41(7,51-18-14-15-28-20-29-16-12-13-17-30(29)43-22-28)37(26(5)34(47)27(6)38(49)53-32)54-39-35(48)31(45(9)10)19-24(3)52-39/h12-17,20,22-27,31-32,35-37,39,48H,11,18-19,21H2,1-10H3,(H,44,50)/b15-14+/t23-,24-,25+,26+,27-,31+,32-,35-,36-,37-,39+,41+,42-/m1/s1 |
| Stdinchikey: | PENDGIOBPJLVBT-HMMOOPTJSA-N |
| C: | 42 |
| H: | 59 |
| N: | 3 |
| O: | 10 |
| Melting Point: | 211 |
| Melting High: | 213 |
Cethromycin, trade name Restanza (initially known as ABT-773[1] [2]) is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP)[1] [3] [4] [5] and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication.[6] Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development.
On October 1, 2008, Advanced Life Sciences submitted a New Drug Application (NDA) to Food and Drug Administration (FDA) for cethromycin to treat mild-to-moderate community acquired pneumonia.[7]
On December 3, 2008, Advanced Life Sciences announced that this New Drug Application has been accepted for filing by the FDA.[8]
In June 2009, an FDA Anti-Infective Drugs Advisory Committee review found insufficient evidence for cethromycin efficacy in treatment of community acquired pneumonia, as the Phase 3 clinical trial followed standards that were updated after the clinical trial but three months prior to review. The committee did, however, find the drug safe to use.[9]